Allan Weinstein - Establishment Labs Independent Director
ESTA Stock | USD 48.95 0.74 1.49% |
Director
Dr. Allan Weinstein is Independent Director of the Company. He is an independent entrepreneur focused on intellectual property in the life sciences and medical device industries. Currently, he is actively associated with the following companies Chairman of Spiritus Pharmaceuticals, from 2012, a specialty pharmaceutical company devoted to improving the lives of those with respiratory diseases Chairman of MinibarRx, LLC, from 2012 to 2017 until its acquisition, a privately held IoT platform company for managing vaccines and biologics with the foremost mission of disease prevention through increased vaccination rates Chairman of ShareStream, from 2003, a leading online video platform and mediamanagement solution provider for education worldwide Chairman of InstantDxOnCallData, from 2000, a pioneer in electronic prescribing and healthcaretransaction services Chairman of Instant Medical Diagnostics, from 2008, a onestep rapiddiagnostic platform and Cofounder of JMed Pharmaceuticals, Inc., a 25yearold privately held intellectual property pharmaceutical company, with a diversified patent portfolio that began with the licensing of both prescription and overthecounter daynight products for cold, cough, and flu. In the past, Dr. Weinstein has served in academic functions including as an Assistant Clinical Professor of Medicine at Georgetown University and as a Consultant to the National Institutes of Health in Bethesda, Maryland, while practicing medicine in Washington, D.C. He received an A.B. in Biology from Lafayette College and an M.D. from the University of Kentucky. Dr. Weinstein is the author of the book Asthma The Complete Guide to SelfManagement of Asthma and Allergies for Patients and Their Families, published by McGrawHill and Random House. He is Boardcertified in Internal Medicine and in Allergy and Clinical Immunology, and completed his medical training fellowship at National Jewish Health in Denver. since 2016.
Age | 68 |
Tenure | 8 years |
Address | Building B15 and 25, Alajuela, Costa Rica |
Phone | 506 2434 2400 |
Web | https://www.establishmentlabs.com |
Allan Weinstein Latest Insider Activity
Tracking and analyzing the buying and selling activities of Allan Weinstein against Establishment Labs stock is an integral part of due diligence when investing in Establishment Labs. Allan Weinstein insider activity provides valuable insight into whether Establishment Labs is net buyers or sellers over its current business cycle. Note, Establishment Labs insiders must abide by specific rules, including filing SEC forms every time they buy or sell Establishment Labs'shares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
Allan Weinstein over six months ago Establishment Labs exotic insider transaction detected |
Establishment Labs Management Efficiency
The company has return on total asset (ROA) of (0.1694) % which means that it has lost $0.1694 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (15.3775) %, meaning that it created substantial loss on money invested by shareholders. Establishment Labs' management efficiency ratios could be used to measure how well Establishment Labs manages its routine affairs as well as how well it operates its assets and liabilities. As of April 25, 2024, Return On Tangible Assets is expected to decline to -0.32. The current year's Return On Capital Employed is expected to grow to -0.29. At present, Establishment Labs' Non Current Assets Total are projected to increase significantly based on the last few years of reporting. The current year's Non Currrent Assets Other is expected to grow to about 4.9 M, whereas Total Assets are forecasted to decline to about 150.6 M.Management Performance
Return On Equity | -15.38 | ||||
Return On Asset | -0.17 |
Establishment Labs Leadership Team
Elected by the shareholders, the Establishment Labs' board of directors comprises two types of representatives: Establishment Labs inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Establishment. The board's role is to monitor Establishment Labs' management team and ensure that shareholders' interests are well served. Establishment Labs' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Establishment Labs' outside directors are responsible for providing unbiased perspectives on the board's policies.
David Hung, Independent Director | ||
Lisa Gersh, Independent Director | ||
Juan Quiros, CEO, Director | ||
Heather Brennan, Head Operations | ||
Nicholas Lewin, Independent Director | ||
Roberto Mezerville, Chief Officer | ||
Lisa Colleran, Independent Director | ||
Paul Rodio, Chief Officer | ||
Renee Gaeta, CFO | ||
Dennis Condon, Independent Director | ||
Salvador Santos, COO | ||
Jeremy Livianu, General Counsel | ||
Alberto Quesada, Vice President Quality & OUS Regulatory Affairs | ||
Edward Schutter, Independent Director | ||
Allan Weinstein, Independent Director | ||
Ivan Bilic, Senior OUS | ||
Eddie Oliveira, Vice President of Sales, Brazil | ||
Ross Mansbach, General Officer | ||
Jeffrey Bettinger, Global People | ||
Neeta Toprani, Corporate Secretary | ||
Rosalyn dIncelli, Medical Clinical | ||
Rajbir Denhoy, Chief Officer | ||
Salvador Dada, Chief Officer | ||
Elizabeth Newman, VP Unit |
Establishment Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Establishment Labs a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Return On Equity | -15.38 | ||||
Return On Asset | -0.17 | ||||
Profit Margin | (0.48) % | ||||
Operating Margin | (0.70) % | ||||
Current Valuation | 1.47 B | ||||
Shares Outstanding | 27.46 M | ||||
Shares Owned By Insiders | 12.30 % | ||||
Shares Owned By Institutions | 78.54 % | ||||
Number Of Shares Shorted | 4.93 M | ||||
Price To Earning | (20.11) X |
Pair Trading with Establishment Labs
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Establishment Labs position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Establishment Labs will appreciate offsetting losses from the drop in the long position's value.Moving together with Establishment Stock
0.68 | NXL | Nexalin Technology | PairCorr |
Moving against Establishment Stock
0.9 | BBLG | Bone Biologics Corp Financial Report 20th of May 2024 | PairCorr |
0.81 | UNH | UnitedHealth Group Financial Report 12th of July 2024 | PairCorr |
0.8 | HCAT | Health Catalyst Financial Report 14th of May 2024 | PairCorr |
0.77 | SINT | SINTX Technologies | PairCorr |
0.7 | HSTM | HealthStream | PairCorr |
The ability to find closely correlated positions to Establishment Labs could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Establishment Labs when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Establishment Labs - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Establishment Labs Holdings to buy it.
The correlation of Establishment Labs is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Establishment Labs moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Establishment Labs moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Establishment Labs can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Establishment Labs Holdings. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in estimate. You can also try the Sectors module to list of equity sectors categorizing publicly traded companies based on their primary business activities.
Complementary Tools for Establishment Stock analysis
When running Establishment Labs' price analysis, check to measure Establishment Labs' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Establishment Labs is operating at the current time. Most of Establishment Labs' value examination focuses on studying past and present price action to predict the probability of Establishment Labs' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Establishment Labs' price. Additionally, you may evaluate how the addition of Establishment Labs to your portfolios can decrease your overall portfolio volatility.
Alpha Finder Use alpha and beta coefficients to find investment opportunities after accounting for the risk | |
Pair Correlation Compare performance and examine fundamental relationship between any two equity instruments | |
Idea Analyzer Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas | |
Global Correlations Find global opportunities by holding instruments from different markets | |
Bonds Directory Find actively traded corporate debentures issued by US companies | |
Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk | |
Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges | |
Idea Optimizer Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio | |
Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets | |
Portfolio Anywhere Track or share privately all of your investments from the convenience of any device |
Is Establishment Labs' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Establishment Labs. If investors know Establishment will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Establishment Labs listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (3.07) | Revenue Per Share 6.451 | Quarterly Revenue Growth (0.28) | Return On Assets (0.17) | Return On Equity (15.38) |
The market value of Establishment Labs is measured differently than its book value, which is the value of Establishment that is recorded on the company's balance sheet. Investors also form their own opinion of Establishment Labs' value that differs from its market value or its book value, called intrinsic value, which is Establishment Labs' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Establishment Labs' market value can be influenced by many factors that don't directly affect Establishment Labs' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Establishment Labs' value and its price as these two are different measures arrived at by different means. Investors typically determine if Establishment Labs is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Establishment Labs' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.